SEOUL – In a decisive move to bolster shareholder value amidst heightening global market volatility, South Korean biopharmaceutical giant Celltrion Inc. announced on Friday that it will expand its planned treasury share cancellation to 9.11 million shares.

The updated plan, disclosed in a regulatory filing on March 6, 2026, marks a significant increase from the previously proposed 6.11 million shares. Based on the closing price as of March 5, the total value of the retired shares is estimated at approximately ₩1.93 trillion (USD 1.45 billion).

 
A Strategic Shift in Capital Management
The 9.11 million shares earmarked for retirement represent 74% of the company's total treasury stock holdings. Celltrion plans to retain the remaining 3.23 million shares (26%) to facilitate future growth engines, including potential M&A activity and strategic partnerships.

A notable highlight of this disclosure is the inclusion of 3 million shares originally reserved for employee stock options. Celltrion has pivoted its strategy to prioritize immediate shareholder returns by canceling these existing shares first. Future employee compensation will instead be managed through the issuance of new shares.

"This 'cancel first, issue later' approach ensures that the total number of outstanding shares remains stable, preventing dilution while maximizing the immediate impact of the stock retirement," a market analyst noted.

Governance Reform and Leadership Changes
The announcement comes ahead of the 35th Annual General Meeting (AGM), where Celltrion aims to set a new standard for corporate governance in the K-biotech sector. The company is proactively introducing several measures to protect minority shareholder interests, including:

-Independent Director System & Cumulative Voting: Mandatory implementation to ensure board diversity and oversight.
-Separate Election of Audit Committee Members: Increasing the number of outside directors elected separately to enhance independence.
-Electronic Shareholder Meetings: Enhancing accessibility for global and retail investors.
The board will also table the approval of a cash dividend of ₩750 per share. Regarding leadership transitions, Shin Min-cheol, President of Celltrion, has been nominated as a new inside director to succeed Vice Chairman Kim Hyoung-ki, who is set to retire.

 
Countering Market Volatility
The timing of this massive capital reduction is seen as a strategic defense mechanism. By reducing the supply of shares in the market, Celltrion aims to stabilize its stock price against the backdrop of geopolitical risks and fluctuating market sentiments.

"This decision is a swift response to extreme market volatility and a reflection of our commitment to maximizing shareholder value," a Celltrion official stated. "We are focused on balancing aggressive shareholder returns with the necessary capital retention for long-term growth."